Steven Kanner

Direttore Tecnico/Scientifico/R&S presso CARIBOU BIOSCIENCES, INC.

Patrimonio netto: 1 M $ in data 31/05/2024

65 anni

32 relazioni

Health Technology

Consumer Services

Commercial Services

Profilo

Steven B.
Kanner is an Independent Director at Specific Biologics, Inc. since 2023 and the Chief Scientific Officer at Caribou Biosciences, Inc. since 2017.
Previously, he worked as the Vice President & Head-Biology at Arrowhead Pharmaceuticals, Inc. from 2013 to 2017.
He completed his undergraduate degree at the University of California, Berkeley and holds a doctorate from The University of Miami Leonard M.
Miller School of Medicine.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
CARIBOU BIOSCIENCES, INC. 0.39%	15/04/2024	354 037 ( 0.39% )	1 M $	31/05/2024

Posizioni attive di Steven Kanner

Società	Posizione	Inizio
CARIBOU BIOSCIENCES, INC.	Direttore Tecnico/Scientifico/R&S	01/06/2017
Specific Biologics, Inc. Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.	Direttore/Membro del Consiglio	10/10/2023

Tutte le posizioni attive di Steven Kanner

Precedenti posizioni note di Steven Kanner

Società	Posizione	Fine
ARROWHEAD PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/06/2017

Vedi nel dettaglio l'esperienza di Steven Kanner

Formazione di Steven Kanner

University of California, Berkeley	Undergraduate Degree
The University of Miami Leonard M. Miller School of Medicine	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Steven Kanner

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
ARROWHEAD PHARMACEUTICALS, INC.	Health Technology
CARIBOU BIOSCIENCES, INC.	Health Technology

Aziende private	1
Specific Biologics, Inc. Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.	Commercial Services